Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELIVERS study of topical diacerein in epidermolysis bullosa simplex
2016-004427-24Phase 2Completed
- Sponsor
- Castle Creek Biosciences
- Start
- May 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of diacerein in epidermolysis bullosa simplex (EBS) (2 arms), sponsored by Castle Creek Biosciences. Primary endpoint: Proportion of subjects achieving at least 40% reduction in body surface area of treated EBS lesions. Started May 2017; status: completed.
02
Drugs
diacerein
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on 2016-004427-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004427-24.